SCHEMBL3023016

SCHEMBL3023016

O=S(=O)(c1cccc(Cl)c1)C1CCN(c2nc(-c3cccc(Br)c3)cs2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.56
RAB9A P51151 6/20 0.56
KDM1A O60341 4/20 0.55
MAOA P21397 3/20 0.55
NPC1 O15118 4/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PTPN1 P18031 1/20 0.42
PTPN6 P29350 1/20 0.42
CDC25A P30304 1/20 0.42
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 2/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HPGD P15428 1/20 0.40
HK1 P19367 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006903 0.94 RAB9A (0.53) SMN1; SMN2RAB9AKDM1AMAOANPC1
SCHEMBL3016185 0.93 RAB9A (0.49) SMN1; SMN2RAB9AKDM1AMAOANPC1
SCHEMBL3000308 0.91 SMN1; SMN2 (0.52) SMN1; SMN2RAB9AKDM1AMAOANPC1
SCHEMBL3022246 0.90 RAB9A (0.51) SMN1; SMN2RAB9AKDM1AMAOANPC1
SCHEMBL3015016 0.90 RAB9A (0.58) SMN1; SMN2RAB9AKDM1AMAOANPC1
SCHEMBL3000517 0.90 SMN1; SMN2 (0.48) SMN1; SMN2RAB9AKDM1AMAOANPC1
SCHEMBL3010751 0.89 RAB9A (0.50) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL2999993 0.89 RAB9A (0.59) SMN1; SMN2RAB9AKDM1AMAOANPC1
SCHEMBL3016646 0.89 RAB9A (0.48) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3010126 0.89 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AKDM1AMAOANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885KDM1A 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.